In Vitro Modeling of Pancreatic Duct Cell Carcinogenesis

Pancreatic adenocarcinoma (PDAC) putatively arises from the pancreatic duct, thus usage of the normal human pancreatic duct epithelial (HPDE) cell line is an ideal model to examine the successive accumulation of genetic alterations involved in carcinogenesis. KRAS mutations have been reported in 90...

Full description

Bibliographic Details
Main Author: Leung, Lisa
Other Authors: Tsao, Ming-Sound
Language:en_ca
Published: 2013
Subjects:
Online Access:http://hdl.handle.net/1807/65513
id ndltd-TORONTO-oai-tspace.library.utoronto.ca-1807-65513
record_format oai_dc
spelling ndltd-TORONTO-oai-tspace.library.utoronto.ca-1807-655132014-06-21T04:15:43ZIn Vitro Modeling of Pancreatic Duct Cell CarcinogenesisLeung, LisaKRASSmad4LCN2NGALpancreatic cancerHPDE0992Pancreatic adenocarcinoma (PDAC) putatively arises from the pancreatic duct, thus usage of the normal human pancreatic duct epithelial (HPDE) cell line is an ideal model to examine the successive accumulation of genetic alterations involved in carcinogenesis. KRAS mutations have been reported in 90% of PDACs. Oncogenic KRAS elicits activation of downstream pathways involved in survival, motility, and cell cycle progression. KRASG12V introduction in the HPDE cell line upregulates Lipocalin-2 (LCN2) expression. LCN2 has been identified in numerous carcinomas and is associated with survival, tumorigenicity, and invasion. In this work, LCN2 was found to be commonly expressed in high grade pancreatic duct neoplastic precursor lesions and PDAC illustrating its potential as a biomarker. Moreover, in vitro and in vivo studies demonstrate that high LCN2 expression promotes gemcitabine resistance, MMP-9 activity, angiogenesis, and tumorigenicity. Loss of Smad4 function is found in 55% of PDAC cases. Smad4 is a critical component in the TGF-β signaling which mediates the transcription of genes involved in processes such as cell cycle arrest, apoptosis, and invasion. This work examined the consequences of KRASG12V expression and Smad4 loss in the HPDE model. Cellular invasion was promoted by KRASG12V expression or knocking down Smad4 by 80% in the HPDE model. A TGF-β resistant HPDE cell line, TβR, was shown to lack Smad4 expression due to deletion, promoter methylation, and nonsense mutation. KRASG12V expression in the TβR model (TβR KRAS) promoted neoplastic transformation and tumour formation in immunodeficient mice with complete penetrance. Smad4 expression in the TβR KRAS cell line reinstated TGF-β signaling, delayed tumour formation, and decreased metastatic spread. This study provides evidence that Smad4 acts as a restriction point in the transformation of HPDE cells. Overall, this work examines the contribution of genes involved in transformation, and identifies a potential therapeutic and diagnostic biomarker in PDAC.Tsao, Ming-Sound2013-062014-06-20T17:04:47ZNO_RESTRICTION2014-06-20T17:04:47Z2014-06-20Thesishttp://hdl.handle.net/1807/65513en_ca
collection NDLTD
language en_ca
sources NDLTD
topic KRAS
Smad4
LCN2
NGAL
pancreatic cancer
HPDE
0992
spellingShingle KRAS
Smad4
LCN2
NGAL
pancreatic cancer
HPDE
0992
Leung, Lisa
In Vitro Modeling of Pancreatic Duct Cell Carcinogenesis
description Pancreatic adenocarcinoma (PDAC) putatively arises from the pancreatic duct, thus usage of the normal human pancreatic duct epithelial (HPDE) cell line is an ideal model to examine the successive accumulation of genetic alterations involved in carcinogenesis. KRAS mutations have been reported in 90% of PDACs. Oncogenic KRAS elicits activation of downstream pathways involved in survival, motility, and cell cycle progression. KRASG12V introduction in the HPDE cell line upregulates Lipocalin-2 (LCN2) expression. LCN2 has been identified in numerous carcinomas and is associated with survival, tumorigenicity, and invasion. In this work, LCN2 was found to be commonly expressed in high grade pancreatic duct neoplastic precursor lesions and PDAC illustrating its potential as a biomarker. Moreover, in vitro and in vivo studies demonstrate that high LCN2 expression promotes gemcitabine resistance, MMP-9 activity, angiogenesis, and tumorigenicity. Loss of Smad4 function is found in 55% of PDAC cases. Smad4 is a critical component in the TGF-β signaling which mediates the transcription of genes involved in processes such as cell cycle arrest, apoptosis, and invasion. This work examined the consequences of KRASG12V expression and Smad4 loss in the HPDE model. Cellular invasion was promoted by KRASG12V expression or knocking down Smad4 by 80% in the HPDE model. A TGF-β resistant HPDE cell line, TβR, was shown to lack Smad4 expression due to deletion, promoter methylation, and nonsense mutation. KRASG12V expression in the TβR model (TβR KRAS) promoted neoplastic transformation and tumour formation in immunodeficient mice with complete penetrance. Smad4 expression in the TβR KRAS cell line reinstated TGF-β signaling, delayed tumour formation, and decreased metastatic spread. This study provides evidence that Smad4 acts as a restriction point in the transformation of HPDE cells. Overall, this work examines the contribution of genes involved in transformation, and identifies a potential therapeutic and diagnostic biomarker in PDAC.
author2 Tsao, Ming-Sound
author_facet Tsao, Ming-Sound
Leung, Lisa
author Leung, Lisa
author_sort Leung, Lisa
title In Vitro Modeling of Pancreatic Duct Cell Carcinogenesis
title_short In Vitro Modeling of Pancreatic Duct Cell Carcinogenesis
title_full In Vitro Modeling of Pancreatic Duct Cell Carcinogenesis
title_fullStr In Vitro Modeling of Pancreatic Duct Cell Carcinogenesis
title_full_unstemmed In Vitro Modeling of Pancreatic Duct Cell Carcinogenesis
title_sort in vitro modeling of pancreatic duct cell carcinogenesis
publishDate 2013
url http://hdl.handle.net/1807/65513
work_keys_str_mv AT leunglisa invitromodelingofpancreaticductcellcarcinogenesis
_version_ 1716704755379601408